Anne C. Chiang - Concepedia

Author

Anne C. Chiang

Also Known As

A. C. Chiang, A. Chiang, A.C. Chiang, A.C.C. Chiang, Aiden Chiang, Anne C Chiang, Anne C. Chiang, Anne Chiang, Chiang, Anne C., Chung, Arlene E.

186

Publications

9.8K

Citations

H-Index

Concepts

All Affiliations

Yale University Yale Cancer Center Memorial Sloan Kettering Cancer Center Sarah Cannon Smilow Cancer Hospital

About

Anne C. Chiang is an author at Yale University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	20	5.5K
2	Health Sciences	5	5	673
3	Arts	1	1	12
4	Nursing	1	1	93
5	Public Health	1	1	14

Anne C. Chiang

Publications

8.4K

Citations

H-Index

Page 1

	Year	Citations
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, The Lancet Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment	2019	2.1K
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial Sarah B. Goldberg, Scott Gettinger, Amit Mahajan, The Lancet Oncology Neuro-oncologyNon-small-cell Lung CancerUntreated Brain MetastasesMedicineEarly Analysis	2016	987
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Clinical Cancer Research	2006	824
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer Scott Gettinger, Jungmin Choi, Katherine Hastings, Cancer Discovery	2017	722
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis Gaorav P. Gupta, Don X. Nguyen, Anne C. Chiang, Nature Lung MetastasisPulmonary CirculationSequential StepsMedicineCancer Growth	2007	720
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, The Lancet Oncology Platinum–etoposide Versus Platinum–etoposideMedicinePathologyImmune Checkpoint InhibitorFirst-line Treatment	2020	662
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial Sarah B. Goldberg, Kurt A. Schalper, Scott Gettinger, The Lancet Oncology Neuro-oncologyPrognostic BiomarkersBiomarker AnalysisBrain MetastasesMedicine	2020	523
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Apar Kishor Ganti, Billy W. Loo, M. Bassetti, Journal of the National Comprehensive Cancer Network	2021	431
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses Taofeek K. Owonikoko, Huifeng Niu, Kristiaan Nackaerts, Journal of Thoracic Oncology	2019	141
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting Carolyn J. Presley, Daiwei Tang, Pamela R. Soulos, JAMA	2018	132

Page 1